Loading clinical trials...
Loading clinical trials...
The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
Collaborators
NCT06958211 · Hidradenitis Suppurativa
NCT06921850 · Hidradenitis Suppurativa
NCT05889182 · Hidradenitis Suppurativa
NCT03146676 · Hidradenitis Suppurativa
NCT05243966 · Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, and more
Research Site
Phoenix, Arizona
Research Site
Bakersfield, California
Research Site
Fremont, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions